Tyrx announced the first implantation of its new AigisRx R Fully Resorbable Antibacterial Envelope has taken place at the Quebec Heart and Lung Institute in Quebec City, Canada by Dr. François Philippon. Tyrx announced on Jan. 31, 2013 that it had received a license from Health Canada to market its AigisRx R Fully Resorbable technology.

Cook Medical has launched the VIVO clinical research study to evaluate the safety and effectiveness of the Zilver Vena Venous Self-Expanding Stent in the treatment of symptomatic iliofemoral venous outflow obstruction. This disease is characterized by leg pain, throbbing, swelling and skin discoloration in the legs. 

Nanomix Inc. has initiated clinical testing in the United States to evaluate the omega-3 cardiac panel.  The panel quantitatively tests whole blood specimens for levels of cardiac troponin I (cTnI), myoglobin and H-FABP, biomarkers often used as an aid in the diagnosis of myocardial infarction (MI). The initial testing will be conducted with approximately 170 normally healthy subjects and will provide baseline performance information that will form the basis of future registration clinical studies. 

At Medanta Hospital in Gurgaon, India, five EchoBox devices were connected to five GE Vivid ultrasound systems, streaming live echo images over the web to experienced sonographers located in the United States.

The Massachusetts General Hospital officially announced the launch of the Mass General Institute for Heart, Vascular and Stroke Care, one of the only institutes in the world to integrate cardiovascular and cerebrovascular care.

The U.S. Food and Drug Administration (FDA) issued a second complete response letter regarding a supplemental new drug application (sNDA) for Xarelto (rivaroxaban) for the reduction of the risk of cardiovascular events in patients with acute coronary syndrome (ACS). Janssen Research and Development LLC is evaluating the letter and will respond to the agency's questions.

Subscribe Now